IP Verse

Treating Fibrosis By Inhibiting Tl1A

Patent No. EP3639841 (titled "Treating Fibrosis By Inhibiting Tl1A") was filed by Cedars Sinai Medical Center on Mar 27, 2014. The application was issued on Sep 6, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSJun 4, 2024D YOUNG
SANOFIMay 9, 2024CARPMAELS & RANSFORD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3639841

CEDARS SINAI MEDICAL CENTER
Application Number
EP19199149A
Filing Date
Mar 27, 2014
Status
Revoked
May 9, 2025
Publication Date
Sep 6, 2023
External Links
Slate, Register , Google Patents